GlaxoSmithKline's AREXVY vaccine has been approved in Canada for adults aged 50-59 to prevent RSV lower respiratory tract disease. The expanded approval follows positive Phase III trial results, with regulatory submissions in Japan and ongoing trials in other age groups.